Here’s Why Investors Are Watching These Five Stocks Today

Page 1 of 2

It’s the middle of earnings season and many investors are hungrily dissecting earnings reports and management commentary to get a better view on earnings outlooks for the future. Among the stocks that have recently reported their financial results are Sony Corp (ADR) (NYSE:SNE), Bristol-Myers Squibb Co (NYSE:BMY), Mastercard Inc (NYSE:MA), United Parcel Service, Inc. (NYSE:UPS), and Celgene Corporation (NASDAQ:CELG). Let’s take a closer look at how each company did in their latest financial quarters and also check how hedge funds are positioned in each stock.

We believe that imitating hedge funds and other large institutional investors can be helpful in identifying stocks capable of outperforming the broader market. Through extensive research that covered portfolios of several hundred large investors between 1999 and 2012, we determined that following the small-cap stocks that large money managers are collectively bullish on, can generate monthly returns nearly 1.0 percentage points above the market (see the details here).

Sony Corp Higher On Earnings

Sony Corp (ADR) (NYSE:SNE)’s stock is modestly higher after the company reported its results for the fourth quarter and full fiscal 2015 ended March 31. The company posted a full-year revenue of 8.1 trillion yen ($71.7 billion), down by 1.3%, while its operating profit surged to 294.2 billion yen Of the around 786 funds we track, 20 funds owned $342.41 million worth of Sony Corp (ADR) (NYSE:SNE)’s shares, which accounted for 1.10% of the float on December 31, versus 21 funds and $328.36 million, respectively, on September 30.

Follow Sony Group Corp (NYSE:SONY)

Bristol-Myers Squibb Turns In Excellent Quarter

Bristol-Myers Squibb Co (NYSE:BMY)’s shares have gained around 2% after the drug giant reported earnings of $0.74 per share on sales of $4.39 billion, versus estimates of $0.65 and $4.25 billion, respectively. Revenue rose 8.7% year-over-year mainly on the back of Bristol-Myers Squibb’s Opdivo, Eliquis, and Hep C franchises. In addition, the company raised its full-year EPS guidance to between $2.37 and $2.47 from the previous $2.30 – $2.40 range, and adjusted full-year EPS guidance to between $2.50 and $2.60 from the previous $2.30-$2.40, and expects 2016 revenue to grow by the low double-digit percentages. The number of funds from our database bullish on Bristol-Myers Squibb Co (NYSE:BMY) fell by three quarter-over-quarter to 59 at the end of December.

Follow Bristol Myers Squibb Co (NYSE:BMY)

On the next page, we examine Mastercard Inc, United Parcel Service Inc, and Celgene Corporation.

Page 1 of 2